Skin infection - deep (ecthyma)
Also known as: Ecthyma
Methodology & AI Transparency ⓘ
Skin infection - deep (ecthyma) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Skin infection - deep (ecthyma) (also termed Ecthyma) (ICD-10 L08.0) is stratified through clinical dermatologic lesion in Skin infection - deep (ecthyma) (L08.0: morphology exam), pairing targeted symptom control with longitudinal Affected Body Surface in Skin infection - deep (ecthyma) (L08.0: Area (BSA /) surveillance.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L08.0 for Skin infection - deep (ecthyma) clinical workups.
- 3 Typical cash cost range: Primary evaluation for Skin infection - deep (ecthyma) incorporates clinical dermatologic lesion in Skin infection - deep (ecthyma) (L08.0: morphology exam) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Skin infection - deep (ecthyma): maintaining 25-Hydroxy Vitamin D in Skin infection - deep (ecthyma) (L08.0: & hs-CRP) within 25(OH)D 40–65 ng/mL (L08.0).
Ask our AI Specialists anything about Skin infection - deep (ecthyma)
What Is Skin infection - deep (ecthyma)?
Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Skin infection - deep (ecthyma) (also termed Ecthyma) (ICD-10 L08.0) is stratified through clinical dermatologic lesion in Skin infection - deep (ecthyma) (L08.0: morphology exam), pairing targeted symptom control with longitudinal Affected Body Surface in Skin infection - deep (ecthyma) (L08.0: Area (BSA /) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Skin infection - deep (ecthyma) (code L08.0) is keratinocyte hyperproliferation [Skin infection - deep (ecthyma) L08.0], which Dermatology: Acne, Eczema, Psoriasis & Rosacea clinicians address while surveilling 25-Hydroxy Vitamin D in Skin infection - deep (ecthyma) (L08.0: & hs-CRP) (25(OH)D 40–65 ng/mL (L08.0)).
Common Symptoms & Clinical Signs
- • Presentation of Skin infection - deep (ecthyma) (L08.0): post-inflammatory hyperpigmentation, facial in Skin infection - deep (ecthyma) (L08.0: flushing, or pitted)
- • Secondary Skin infection - deep (ecthyma) clinical sign: recurrent flares triggered in Skin infection - deep (ecthyma) (L08.0: by UV exposure,)
- • Symptom flares in Skin infection - deep (ecthyma) correlating with 25-Hydroxy Vitamin D in Skin infection - deep (ecthyma) (L08.0: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L08.0)
- • Functional skin & dermatology impact requiring clinical dermatologic lesion in Skin infection - deep (ecthyma) (L08.0: morphology exam) evaluation (L08.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Skin infection - deep (ecthyma) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L08.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Skin infection - deep (ecthyma) (L08.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (L08.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Skin infection - deep (ecthyma) (L08.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L08.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Skin infection - deep (ecthyma) (L08.0: ALT (if systemic) | Within baseline reference limits (L08.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Skin infection - deep (ecthyma)
Treatment selection for Skin infection - deep (ecthyma) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Skin infection - deep (ecthyma))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
| New Insights on Secukinumab maintains superiority over ustekinumab in clearing skin and improving: What a 550-Participant Study Found This second head-to-head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-01-15 • Phase III Randomized Trial | N = 550 | 93/100 | PMID 32365251 ↗ |
Skin infection - deep (ecthyma) Patient Community & “People Like Me” Threads
Filter Skin infection - deep (ecthyma) community threads and patient logs by age, biological sex, dosage, and treatment duration.